Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
AssigneesUniversitaetsklinikum Freiburg, Baker IDI Heart and Diabetes Institute Holdings Limited
InventorsAndreas ZIRLIK, Dennis WOLF, Karlheinz PETER
Life of this patent
Estimating the term…
Abstract
The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
Claims9
An antibody capable of specifically binding to an epitope comprising the amino acid sequence QLK.
An antibody capable of inhibiting the binding of macrophage-1 antigen (Mac-1) to CD40L.
Dependencies are inferred from the claim text.